1st Quarter - Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$2,560,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Research and experimentation tax incentives and international tax issues, including: Administrations FY 2014 corporate tax proposals, Tax Reform, including House Ways and Means and Senate Finance Committee Discussion Drafts

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
NANCY ELLEN MCCARTHY —

Contacted: Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Office of Management & Budget (OMB)

Copyright/Patent/Trademark CPT

H.R. 3309 The Innovation Act of 2013 (heightened pleading standards, discovery stay) S. 1720, The Patent Transparency and Improvements Act (demand letters, customer stay) S. 1013, The Patent Abuse Reduction Act (heightened pleading standards, discovery stay) S. 1612, The Patent Litigation Integrity Act (bonding)Trans-Pacific Partnership (12 years data exclusivity) S. 866, The Patient Quality Improvement Act (covered business method patents)

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
WILLIAM O'BRIEN —
HELEN RHEE —

Contacted: SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health Resources & Services Administration (HRSA)

Bills named: S. 1013 (113th), S. 866 (113th), S. 1612 (113th), S. 1720 (113th), H.R. 3309 (113th)

Health Issues HCR

S. 3187, The Food and Drug Safety and Innovation Act (user fee sequester) Biosimilars, no specific bill Health Resources and Services Administration (HRSA) policy regarding rebates on drugs used in the outpatient setting to help low-income/uninsured populations (340B), no specific bill

LobbyistCovered position, as disclosed
RUTH HOFFMAN —
WILLIAM O'BRIEN —
HELEN RHEE —

Contacted: Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3187 (113th)

Medicare/Medicaid MMM

End Stage Renal Disease and issues related to dialysis Medicare Part B drug reimbursement issues (Average Sales Price) H.R. 2810, Medicare Patient Access and Quality Improvement Act of 2013 (Medicare Physician Payments) Medicare Part D drug reimbursement issues (six protected classes)H.R. 4302, Protecting Access to Medicare Act of 2014 (Medicare Physician Payments, end stage renal disease prospective payment system bundling issues)

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
CHAKA BURGESS —
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: Office of Management & Budget (OMB); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA)

Bills named: H.R. 4302 (113th), H.R. 2810 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.